GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nirvana Life Sciences Inc (XCNQ:NIRV) » Definitions » ROE %

Nirvana Life Sciences (XCNQ:NIRV) ROE % : Negative Equity% (As of Jan. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nirvana Life Sciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Nirvana Life Sciences's annualized net income for the quarter that ended in Jan. 2024 was C$0.02 Mil. Nirvana Life Sciences's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was C$-0.83 Mil. Therefore, Nirvana Life Sciences's annualized ROE % for the quarter that ended in Jan. 2024 was Negative Equity%.

The historical rank and industry rank for Nirvana Life Sciences's ROE % or its related term are showing as below:

During the past 6 years, Nirvana Life Sciences's highest ROE % was Negative Equity%. The lowest was 0.00%. And the median was Negative Equity%.

XCNQ:NIRV's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.45
* Ranked among companies with meaningful ROE % only.

Nirvana Life Sciences ROE % Historical Data

The historical data trend for Nirvana Life Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nirvana Life Sciences ROE % Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23
ROE %
Get a 7-Day Free Trial Negative Equity - - - -

Nirvana Life Sciences Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - Negative Equity

Competitive Comparison of Nirvana Life Sciences's ROE %

For the Biotechnology subindustry, Nirvana Life Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nirvana Life Sciences's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's ROE % falls into.



Nirvana Life Sciences ROE % Calculation

Nirvana Life Sciences's annualized ROE % for the fiscal year that ended in Apr. 2023 is calculated as

ROE %=Net Income (A: Apr. 2023 )/( (Total Stockholders Equity (A: Apr. 2022 )+Total Stockholders Equity (A: Apr. 2023 ))/ count )
=-1.487/( (-0.162+-0.936)/ 2 )
=-1.487/-0.549
=N/A %

Nirvana Life Sciences's annualized ROE % for the quarter that ended in Jan. 2024 is calculated as

ROE %=Net Income (Q: Jan. 2024 )/( (Total Stockholders Equity (Q: Oct. 2023 )+Total Stockholders Equity (Q: Jan. 2024 ))/ count )
=0.02/( (-0.846+-0.812)/ 2 )
=0.02/-0.829
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Nirvana Life Sciences  (XCNQ:NIRV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=0.02/-0.829
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.02 / 0)*(0 / 0.137)*(0.137 / -0.829)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=0.02/-0.829
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0.02 / 0.02) * (0.02 / -0.68) * (-0.68 / 0) * (0 / 0.137) * (0.137 / -0.829)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * -0.0294 * N/A % * 0 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Nirvana Life Sciences ROE % Related Terms

Thank you for viewing the detailed overview of Nirvana Life Sciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nirvana Life Sciences (XCNQ:NIRV) Business Description

Traded in Other Exchanges
N/A
Address
650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is focused on developing medical products and regimens that address addiction. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.

Nirvana Life Sciences (XCNQ:NIRV) Headlines

No Headlines